NO20090327L - Nye forbindelser 384 - Google Patents

Nye forbindelser 384

Info

Publication number
NO20090327L
NO20090327L NO20090327A NO20090327A NO20090327L NO 20090327 L NO20090327 L NO 20090327L NO 20090327 A NO20090327 A NO 20090327A NO 20090327 A NO20090327 A NO 20090327A NO 20090327 L NO20090327 L NO 20090327L
Authority
NO
Norway
Prior art keywords
compound
present
new connections
relates
formula
Prior art date
Application number
NO20090327A
Other languages
English (en)
Inventor
Didier Rotticci
Tobias Rein
Ulrika Yngve
Fernando Huerta
Torben Pedersen
Karin Staaf
Jeremy Burrows
Fredrik Lake
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38846127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090327(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20090327L publication Critical patent/NO20090327L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår en forbindelse med formel (I): som en fri base eller et farmasøytisk akseptabelt salt derav. Foreliggende oppfinnelse angår også farmasøytiske formuleringer som inneholder nevnte forbindelse og anvendelsen av nevnte forbindelse ved behandling. Foreliggende oppfinnelse angår videre en fremgangsmåte for fremstilling av en forbindelse med formel (I) og nye intermediater anvendt deri.
NO20090327A 2006-06-27 2009-01-21 Nye forbindelser 384 NO20090327L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81675606P 2006-06-27 2006-06-27
PCT/SE2007/000620 WO2008002244A2 (en) 2006-06-27 2007-06-26 Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)

Publications (1)

Publication Number Publication Date
NO20090327L true NO20090327L (no) 2009-02-09

Family

ID=38846127

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090327A NO20090327L (no) 2006-06-27 2009-01-21 Nye forbindelser 384

Country Status (20)

Country Link
US (1) US20080188502A1 (no)
EP (1) EP2046782A4 (no)
JP (1) JP2009542638A (no)
KR (1) KR20090024817A (no)
CN (1) CN101511825A (no)
AR (1) AR061652A1 (no)
AU (1) AU2007265731A1 (no)
BR (1) BRPI0713576A2 (no)
CA (1) CA2655441A1 (no)
CL (1) CL2007001881A1 (no)
CO (1) CO6140059A2 (no)
EC (1) ECSP088973A (no)
IL (1) IL195666A0 (no)
MX (1) MX2008015720A (no)
NO (1) NO20090327L (no)
RU (1) RU2008148902A (no)
TW (1) TW200815418A (no)
UY (1) UY30440A1 (no)
WO (1) WO2008002244A2 (no)
ZA (1) ZA200810484B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007036732A1 (en) 2005-09-30 2007-04-05 Astrazeneca Ab Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
AR058073A1 (es) * 2005-10-03 2008-01-23 Astrazeneca Ab Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
CL2007001873A1 (es) * 2006-06-27 2008-01-04 Takeda Pharmaceutical Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo
TW200815417A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds II
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2406230A1 (en) 2009-03-11 2012-01-18 Pfizer Inc. Substituted indazole amides and their use as glucokinase activators
RU2011140238A (ru) * 2009-04-15 2013-05-20 Астразенека Аб Имидазол-замещенные пиримидины, полезные в лечении заболеваний, ассоциированных с киназой-3 гликогенсинтазы, таких как болезнь альцгеймера
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN103724207B (zh) * 2013-12-20 2016-07-06 北京智博高科生物技术有限公司 苯基苄基醚类衍生物及其制备方法和应用
EP3741375A1 (en) 2014-07-17 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating neuromuscular junction-related diseases
UY36547A (es) 2015-02-05 2016-06-01 Bayer Cropscience Ag Derivados heterocíclicos condensados bicíclicos sustituidos por 2-(het)arilo como pesticidas
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections
CN108137548A (zh) 2015-08-07 2018-06-08 拜耳作物科学股份公司 作为农药的2-(杂)芳基取代的稠合杂环衍生物
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
EP1554269A1 (en) * 2002-07-09 2005-07-20 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
CA2533870A1 (en) * 2003-07-30 2005-02-10 Shudong Wang Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
CA2542880A1 (en) * 2003-10-21 2005-05-12 Cyclacel Limited Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US20090099160A1 (en) * 2004-12-17 2009-04-16 David Andrews 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors
GB0504753D0 (en) * 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
AR058073A1 (es) * 2005-10-03 2008-01-23 Astrazeneca Ab Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
TW200815417A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds II

Also Published As

Publication number Publication date
EP2046782A4 (en) 2010-10-13
UY30440A1 (es) 2008-01-31
TW200815418A (en) 2008-04-01
EP2046782A2 (en) 2009-04-15
IL195666A0 (en) 2009-09-01
JP2009542638A (ja) 2009-12-03
CL2007001881A1 (es) 2008-02-08
CA2655441A1 (en) 2008-01-03
ZA200810484B (en) 2009-08-26
AR061652A1 (es) 2008-09-10
ECSP088973A (es) 2009-01-30
RU2008148902A (ru) 2010-08-10
AU2007265731A1 (en) 2008-01-03
KR20090024817A (ko) 2009-03-09
WO2008002244A2 (en) 2008-01-03
BRPI0713576A2 (pt) 2012-10-23
CO6140059A2 (es) 2010-03-19
US20080188502A1 (en) 2008-08-07
WO2008002244A3 (en) 2008-02-14
WO2008002244A8 (en) 2008-10-09
CN101511825A (zh) 2009-08-19
MX2008015720A (es) 2008-12-19

Similar Documents

Publication Publication Date Title
NO20090328L (no) Nye forbindelser 385
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20083411L (no) Indaneddiksyrederivater og deres anvendelse som farmasoytiske midler, intermediater og fremgangsmater for fremstilling
NO20091560L (no) Biaryleterureaforbindelser
NO20082496L (no) Pyrazinderivater
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
CY1109962T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας
NO20063761L (no) Sulfonamidderivater for behandling av sykdommer
NO20076638L (no) Nye 8-sulfonylamino-3-aminosubstituerte kroman- eller tetrahydronaftalenderivater som modulerer 5HT6-reseptoren
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
NO20063468L (no) Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister
NO20066055L (no) Pyridinderivater
NO20063928L (no) Substituerte kinolinforbindelser
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
IS2376B (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi
NO20062905L (no) Nye hydroksaminsyreestere og farmasoytisk anvendelse derav
CY1106857T1 (el) Βενζαμιδια 4-(αμινομεθυλ)-πιπεριδινης ως 5ht4-ανταγωνιστες
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20055977L (no) Nye benzimidazolderivater
UA84048C2 (ru) Производные сульфонамида для лечения заболеваний, способ их получения (варианты), фармацевтическая композиция на их основе
WO2008002244A3 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application